This new booster dose will be recommended during a new vaccination campaign, coupled with that against influenza.
The High Authority for Health (HAS) gives the green light to three anti-Covid-19 vaccines adapted to Omicron for a new booster vaccination campaign planned for the fall and Coupled with that against influenza, it announced on Tuesday 20 September in a press release.
This new booster dose will be recommended to people at risk of a severe form, to those around them and to caregivers. The HAS recommends “either one of the three bivalent vaccines– two developed by Pfizer/BioNTech, the third by Moderna – recently validated by the European Medicines Agency.
“Vaccines adapted to circulating strains”
“Based on the available data and in an epidemic context marked by the majority circulation of the BA.5 sub-variant“, the HAS recommends as an employer “preferably» one of these vaccines, all messenger RNA, for a new automatic booster dose. This recommendation applies regardless of the anti-Covid vaccine administered to the person.
“Like seasonal influenza vaccines, updated each year to take into account the viruses that are most likely to circulate during the winter, bivalent mRNA vaccines are not new vaccines but vaccines adapted to circulating strains.“, underlines the HAS in its press release.
These are the Moderna and Pfizer/BioNTech vaccines targeting the original strain of the virus and the Omicron BA.1 variant, and the Pfizer/BioNTech vaccine targeting the original strain and the BA subvariants .4 and BA.5 from Omicron.
Cases of infections on the rise
At the same time, the HAS has its recommendation to couple the vaccination reminder campaign against Covid-19 with that of vaccination against influenza, which will start on October 18. A concomitant injection or the same day of the two vaccines is possible, she recalls.
“In the immediate future and because the number of cases of infections has started to rise again for a few days», this health authority recommends not to postpone the second booster dose in people over 60 and under 60 at risk of severe form who have not received it within the recommended time frame. It recalls the effectiveness of current vaccines (monovalent) against severe forms of Covid-19.
SEE ALSO – Covid-19: Moderna sues Pfizer and BioNTech for patent infringement on the vaccine